BioSpace News Archive

Science Applications International Corp. (NYSE: SAIC ) today announced the appointment of two new senior vice presidents of Human Resources (HR) and a new corporate controller.

Eurofins (Paris:ERF), through its empowerDX subsidiary, and Rite Aid announce the launch of an over-the-counter, FDA-authorised[1], at-home COVID-19 PCR Test Kit.

NLS Pharmaceutics Ltd. announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present a corporate overview at the First Annual Access to Giving Virtual Investor Conference on July 13-15, 2021.

VistaGen Therapeutics today announced that management will participate in the ‘Updates in Neuropsych’ panel at the virtual William Blair Biotech Focus Conference 2021 on July 15, 2021 at 9:00 a.m.

Foghorn Therapeutics Inc. today announced that Adrian Gottschalk, President & Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15.

Bacainn Therapeutics, Inc. today presented results at the European Crohn’s and Colitis Organisation’s 2021 Virtual Congress from a Phase 1 study that showed its lead asset BT051 was safe and well-tolerated in healthy adults. BT051 is an oral, locally-acting inhibitor of neutrophil trafficking and activation and is in clinical development for the treatment of inflammatory bowel disease (IBD), which impacts as many as 6.8 million people in the United States and Europe

RhoVac AB (“RhoVac”), a Swedish cancer immunotherapy company, announces today on July 9th 2021, that its Safety Monitoring Committee has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac.

ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of pre-clinical data highlighting the safety and anti-tumor efficacy of ABL503/TJ-L14B in the Journal for ImmunoTherapy of Cancer(JITC).

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new three-year data from the long-term extension of the STELARA® Phase 3 UNIFI study.

St. Jude Children’s Research Hospital scientists and collaborators in Sweden and Japan are reporting that the enzyme NUDT15 plays a role in how patients respond to antiviral therapy with the common drugs ganciclovir and acyclovir.